ArticleJournal of acquired immune deficiency syndromes (1999)2025
Predictive markers for sustained viral suppression on dual bNAbs during ART interruption in children.
Article in Journal of acquired immune deficiency syndromes (1999), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03707977 (A Clinical Trial to Evaluate the Impact of Broadly Neutralizing Antibodies VRC01LS and 10-1074 on Maintenance of HIV Suppression in a Cohort of Early-Treated Children in Botswana), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Clinical Trial to Evaluate the Impact of Broadly Neutralizing Antibodies VRC01LS and 10-1074 on Maintenance of HIV Suppression in a Cohort of Early-Treated Children in Botswana (Dual bNAb Treatment in Children)
Who cites it
1 citing paper in PubMed.
- Long-Term Clinical, Immunologic, and Viral Reservoir Outcomes in Children Treated With VRC01LS and 10-1074 Monoclonal Antibodies in the Tatelo Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundSimple clinical markers may predict favorable outcomes in pediatric HIV treatment and cure trials. We report findings for biomarker combinations evaluated during the broadly neutralizing antibodies (bNAbs)-only step of the Tatelo Study in Botswana.
methodsTwenty-five children who were on ART since birth received up to 24 weeks of bNAb-only treatment (VRC01LS+10-1074). Suppression was defined as maintaining HIV RNA<400 copies/mL. HIV qualitative DNA and HIV RNA were performed every 1-2 weeks and enzyme immunosorbent assay (EIA) every 4-8 weeks.
resultsThe median age of children at study entry was 3.7 years (IQR 3.1-4.4). At the start of bNAb-only treatment, 13/25 (52%) had negative qualitative DNA, 17/25 (68%) had negative EIA, and 10/25 (40%) were negative for both. Nine of 13 (69%) with negative qualitative DNA remained suppressed compared with 2/12 (17%) with positive or indeterminate qualitative DNA (OR 11.3, 95% CI 1.7-76.9). Nine of 17 (53%) with negative EIA remained suppressed compared with 2/8 (25%) with positive EIA (OR 3.4, 95% CI 0.5-21.7). Combining biomarkers, 8/10 (80%) who were negative/negative remained suppressed, compared with 3/15 (20%) with any other pattern (OR 16.0, 95% CI 2.2-118.3). In the visit immediately prior to viral rebound, HIV RNA target detection occurred in 1/14 (7%) of failures.
conclusionAt the start of bNAb-only treatment, negative qualitative DNA, and especially negative/negative DNA and EIA, have potential to predict maintenance of viral suppression among children on dual bNAbs. HIV RNA target detection below the assay limit did not prove to be a clinically useful biomarker in the visits preceding failure.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.